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Abstract: Autophagy can result in cellular adaptation, as well as cell survival or cell death. Modulation
of autophagy is increasingly regarded as a promising cancer therapeutic approach. Ginsenoside
compound K (CK), an active metabolite of ginsenosides isolated from Panax ginseng C.A. Meyer,
has been identified to inhibit growth of cancer cell lines. However, the molecular mechanisms
of CK effects on autophagy and neuroblastoma cell death have not yet been investigated. In the
present study, CK inhibited neuroblastoma cell proliferation in vitro and in vivo. Treatment by
CK also induced the accumulation of sub-G1 population, and caspase-dependent apoptosis in
neuroblastoma cells. In addition, CK promotes autophagosome accumulation by inducing early-stage
autophagy but inhibits autophagic flux by blocking of autophagosome and lysosome fusion, the
step of late-stage autophagy. This effect of CK appears to be mediated through the induction of
intracellular reactive oxygen species (ROS) and mitochondria membrane potential loss. Moreover,
chloroquine, an autophagy flux inhibitor, further promoted CK-induced apoptosis, mitochondrial
ROS induction, and mitochondria damage. Interestingly, those promoted phenomena were rescued
by co-treatment with a ROS scavenging agent and an autophagy inducer. Taken together, our findings
suggest that ginsenoside CK induced ROS-mediated apoptosis and autophagic flux inhibition, and
the combination of CK with chloroquine, a pharmacological inhibitor of autophagy, may be a novel
therapeutic potential for the treatment of neuroblastoma.
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1. Introduction
Neuroblastoma is the second most prominent type of solid tumor in childhood, with more than
50% of cases occurring within two years of birth [1,2]. Despite advances in treatment modalities
such as surgery, radiation therapy, and chemotherapy, neuroblastoma is generally progressive and
very malignant, with long-term survival rates of <40% for children with advanced and metastatic
disease [3–5]. Presently, the development of alternative medicines derived from plants with low side
effects is being studied extensively [6]. Accumulating evidence reveals that these anticancer drugs
induce various cell death mechanisms, including apoptosis and autophagy in several types of cancer
cells [7–9]. Autophagy and apoptosis play an important role in determining cancer cell fate and are
essential metabolic pathways for organism homeostasis, organ development, and cancer [8]. Apoptosis
is a selective physiological process in which activation of caspases (cysteine aspartyl proteases) results in
mitochondrial membrane permeability and morphological changes, including chromatin condensation
and DNA fragmentation, thereby leading to programmed cell death [10]. Failure of apoptosis is
thought to contribute to tumorigenesis, because it regulates the balance between cell proliferation and
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death. Therefore, targeting of key apoptotic modulators has become a strategy for the development of
cancer therapies [11,12].
Similarly, autophagy is an evolutionarily conserved catabolic process of lysosomal degradation
of cytoplasmic content in eukaryotes [12]. This autophagic pathway includes vesicle elongation,
autophagosome maturation (sequestration of cargo), autophagosome–lysosome fusion, and
degradation [13]. It provides energy for cell functions through degradation of molecules and
cellular organs but also reduces cell damage by promoting the elimination of pathogens, toxic
molecules, damaged cellular organelles, and misfolded proteins. However, excess autophagy can
induce autophagic cell death by excessive degradation of mitochondria and damaged molecules
required for cell survival [14–16]. Autophagy acts like a “double-edged sword” that plays a positive
or negative role in cancer cells during the tumorigenesis process. Whether autophagy increases or
inhibits cell death in response to cellular stress remains questionable [17]. Therefore, to balance cell
survival and death, it is necessary to understand the complexity of the relationship between cancer cell
apoptosis and autophagy.
Panax ginseng C.A. Meyer has been used as a health product and natural remedy in traditional
medicine in many Asian countries such as China, Korea, and Japan for thousands of years [18].
Ginsenoside (ginseng saponins) is the major active component of ginseng, and more than 20
ginsenosides have been reported to possess various biological activities, including anti-inflammation,
anti-carcinogenesis, anti-metastasis, and neuroprotection [19–22]. Compound K (CK) is a major
metabolite component of several protopanaxadiol type (PPD) ginsenosides (Rb1, Rb2, and Rc) that is
secreted by intestinal bacteria in humans and rats through the multistage cleavage of sugar moieties [23].
CK is a derivative of the PPD-ginsenoside, and its chemical formula is C36H62O8 with a molecular
weight of 622.86 g/mol (Figure 1A). The biological function of CK has been explored for its antitumor
and anti-inflammatory effects in several disease models [18,24,25]. CK blocks proliferation and
migration of tumor cells and promotes apoptosis and autophagy [26–28]. However, its mechanism of
action in neuroblastoma cells is unknown. Therefore, in the present study, we aimed to investigate the
anticancer effects of CK and its underlying mechanisms on crosstalk between apoptosis and autophagy
in neuroblastoma cell lines.
2. Results
2.1. CK Inhibits the Growth of Human Neuroblastoma Cells
To investigate the effect of CK on the growth of human neuroblastoma cells, three neuroblastoma
cell lines, SK-N-BE(2), SH-SY5Y, and SK-N-SH cells, were cultured in the presence of various
concentrations of CK (0–20 µM) for 24 h, and the cell viability was then assessed using a CCK-8
assay. A 24 h CK treatment significantly inhibited the growth of three neuroblastoma cell lines in
a dose-dependent manner, with IC50 values of 5 µM [SK-N-BE(2)], 7 µM (SH-SY5Y), and 15 µM
(SK-N-SH) cells, respectively (Figure 1B). SK-N-BE(2) and SH-SY5Y cells were more sensitive to CK
than SK-N-SH cells, so these two cells were used for subsequent studies. Alternatively, CK showed no
obvious anti-growth effects on CCD-1079SK, BJ, and HUVEC, as models of normal cells (Figure 1B).
Following CK treatment, morphological changes of cells were observed by phase-contrast microscopy.
Morphological changes included cell shrinkage, increased cell floating, and reduced cell attachment
compared to untreated control cells (Figure 1C). To further confirm the inhibitory effect of CK on
the proliferation of SK-N-BE(2) and SH-SY5Y cells, a colony formation assay was performed. As a
result, the number of colonies was decreased in a dose-dependent manner after treatment with CK in
both SK-N-BE(2) and SH-SY5Y cells (Figure 1D). Altogether, these results suggest that CK can inhibit
neuroblastoma cell proliferation without affecting normal cells.
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Figure 1. CK induces cell death in neuroblastoma cells. (A) Chemical structure of CK. (B,C) Three 
different neuroblastoma cells and normal cells were treated in various concentrations (0, 2, 5, 10, 15, 
and 20 µM) with CK, and cell viability was determined by CCK-8 assay. Data are presented as the 
mean ± SD of three independent experiments. *: p < 0.05 or **: p < 0.01 versus control. (C) Cell 
morphology change induced by CK treatment and cell morphology were observed under a 
microscope. Scale bar: 50 µm. (D) Representative images of colony formation assay in SK-N-BE(2) 
and SH-SY5Y. Data are presented as the mean ± SD of three independent experiments. *: p < 0.05 or***: 
p < 0.001 compared to control. CK, Ginsenoside compound K. 
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Figure 1. CK induces cell death in neuroblastoma cells. (A) Chemical structure of CK. (B,C) Three
different neuroblastoma cells and normal cells were treated in various concentrations (0, 2, 5, 10, 15, and
20 µM) with CK, and cell viability was determined by CCK-8 assay. Data are presented as the mean ±
SD of three independent experiments. *: p < 0.05 or **: p < 0.01 versus control. (C) Cell morphology
change induced by CK treatm nt and cell morphology w re observed und r a microscope. Scale bar:
50 µ . (D) Representative images of colony formation assay in SK-N-BE(2) and SH-SY5Y. Data are
presented as the me n ± SD of three independent experim nts. *: p < 0.05 or ***: p < 0.001 compared to
control. CK, Ginsenoside compound K.
2.2. CK Induces Cell Cycle Arrest and Apoptotic Cell Death in Neuroblastoma Cells
To determine the underlying mechanisms by which CK exerts cytotoxicity, we examined the cell
cycle distribution in SK-N-BE (2) cells. SK-N-BE(2) cells were treated with various concentrations of
CK for 24 h and then flow cytometry was performed. The results showed that CK significantly induced
accumulation of the sub-G1population (apoptotic cells) in a dose-dependent manner (Figure 2A,B).
Moreover, CK treatment increased the level of P21 protein, a potent inhibitor of cell cycle progression in
SK-N-BE(2) and SH-SY5Y cells (Figure 2C). These results suggest that the CK-inhibited cell proliferation
was due to cell cycle arrest at the sub-G1 phase in neuroblastoma cells.
To confirm the cell death in CK-treated SK-N-BE(2), we performed Hoechst/PI staining. For
Hoec st/PI staining, SK-N-BE(2) cells were treated with various concentrations of CK for 24 h, and
morphological changes of cells were observed by fluorescence microscopy. Ho chst 33342 d e is a
membr ne-permeable dye but PI is not. As membrane permeability increases in necrosis or l er stages
of apoptosis, PI forms a bright red, fluorescent complex across cell membranes. All nucleated cells can
be stained blue with Hoechst 33342. Condensed and fragmented apoptotic cells stain brighter than
normal nuclei do, so that apoptotic cells can be distinguished from living cells [10]. Cell nuclei emitting
a fluorescence signal from both Hoechst and PI (fluorescence co-localization) were considered to be
dead cells, while cells emitting only Hoechst signal were counted as live cells (Figure 2D). Cell death
was quantitated by four visual fields randomly selected for each sample and the results were expressed
as the ratio of PI positive cells to total cells (Hoechst positive cells). CK treatment in SK-N-BE(2) cells
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caused 20.5%, 31.3%, and 43.6% cell death at 5, 10, and 20 µM, respectively (Figure 2E). Next, we
performed the flow cytometry using Annexin V-FITC/PI double staining. As shown in Figure 2F,G, CK
significantly increased apoptotic cells in a dose-dependent manner in SK-N-BE(2) and SH-SY5Y cells.
These findings suggest that CK can induce apoptotic cell death in neuroblastoma cells.Int. J. Mol. Sci. 2019, 20, x 5 of 24 
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expression of P21 protein levels was examined by western blot after CK treatment for 24 h in 
neuroblastoma cells. (D) Nuclear structures of SK-N-BE(2) cells were analyzed via fluorescence 
microscope. The cells were fixed and stained with Hoechst 33342/PI solution for 10 min at room 
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Figure 2. CK induced cell cycle arrest and apoptotic cell death in neuroblastoma cells. (A) Cell cycle
distribution of SK-N-BE(2) cells treated with 0, 5, 10, and 20 µM CK for 24 h was detected and analyzed
by flow cytometry following staining with PI. Quantitative analysis of cells in each cell cycle phase was
performed. (B) Representative images of flow cytom try are shown. The xperiment was rep ated in
triplicate. Data represent mean ± SD. *: p < 0.05 or **: p . 1 versus control. (C) The expression of
P21 protein levels was examin d by estern blot after CK treatmen for 24 h in n uroblastoma cells.
(D) Nuclear structures of SK- -BE(2) cells were analyzed via fluorescence microscope. The cells were
fixed and stained with Hoechst 33342/PI solution for 10 min at room temperature. (E) The ratio of
PI staining (red) and Hoechst 33342 staining (blue) represented cell death rates. Data are presented
as the mean ± SD of three independent experiments. ***: p < 0.001 versus control. Scale bar: 50 µm.
(F) Apoptotic cell death was determined by Annexin V/PI flow cytometry analysis. SK-N-BE(2) and
SH-SY5Y cells were treated with different concentrations of CK (0, 5, 10, 20 µM) for 24 h. The results
shown are representative of three independent cytometric analyses. Histograms illustrate the number
of cells undergoing apoptosis. (G) The percentage of apo totic cells is shown. Data are mean ± SD of
three independent experiments. *: p < 0.05, **: p < 0.01 versus control group.
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2.3. CK Induces Apoptotic Cell Death in Neuroblastoma Cells via Caspase Dependent- Pathways
To explore the molecular mechanism of CK-induced apoptosis, we performed reverse transcription
polymerase chain reaction (RT-PCR) and Western blots for apoptosis-related proteins. The expression of
apoptosis-related genes (Bcl-2, Bax, Caspase-3, Caspase-9, PUMA, and Noxa) was measured in SK-N-BE(2)
cells after 5 µM CK treatment for the indicated time. The results revealed that CK upregulated
pro-apoptotic genes, including Caspase-9, Caspase-3, Bax, Noxa, and PUMA, in a time-dependent
manner (Figure 3A,B). Meanwhile, CK significantly decreased the expression of anti-apoptotic gene
Bcl-2 in SK-N-BE(2) cells. In western blots, the protein level of cleaved caspase-3, caspase-8, and
poly(ADP-ribose) polymerase (PARP) was significantly upregulated in SK-N-BE(2) and SH-SY5Y cells
in a dose-dependent manner (Figure 3C–F). The Bcl-2 family proteins are known to be involved in
the mitochondrial-mediated apoptosis pathway that activates the caspase cascade. Our results show
that Bcl-2 family protein expressions, Bcl-2 and Bcl-xL (anti-apoptotic proteins), were downregulated
(Figure 3C–F). These results indicate that CK strongly induces apoptosis in SK-N-BE(2) and SH-SY5Y
cells by triggering caspase activation.
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Figure 3. CK induces apoptotic cell death of human neuroblastoma cells. (A) mRNA expression levels of
apoptotic genes, Bcl-2, Bax, Caspase-3, Caspase-9, PUMA, and Noxa, were evaluated by semi-quantitative
reverse transcription polymerase chain reaction. (B) Data were obtained from at least three independent
experiments and values are presented as the mean ± SD. *: p < 0.05, **: p < 0.01 versus control group.
(C–F) Quantification of the protein levels were tested by west rn blot in SK-N-BE(2) a d SH-SY5Y
cells. Glyceraldehy e 3-phosphate dehydrogenase (GAPDH) was used as an RNA and protein loading
control. Band intensities were quantitatively analyzed using the Image J program, and bar graphs in
(D) and (F) are represented as mean ± SD of three independent experiments. *: p < 0.05, **: p < 0.01
versus control group. CK, Ginsenoside compound K. (G) Neuroblastoma cells were pretreated with or
without 20 µM Z-VAD-FMK for 3 h and then treated with or without CK for 24 h. Cell viability was
analyzed using the CCK-8 assay. Data error bars correspond to the mean ± SD of three independent
experiments. **: p < 0.01 versus the control and ##: p < 0.01 versus CK-treated cells.
To elucidate further how CK induces NB cell death by apoptosis via caspase activation, we used
a pan caspase inhibitor, Z-VAD-FMK. CCK-8 analysis showed that pretreatment with Z-VAD-FMK
blocked cytotoxic effects induced by CK treatment in neuroblastoma cells (Figure 3G). This result
suggests that CK induces caspase-dependent apoptosis in neuroblastoma cells.
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2.4. CK-induced Apoptosis Involves ROS Generation in Neuroblastoma Cells
Intracellular reactive oxygen species (ROS) production by mitochondria has been reported to be
closely related to apoptosis in various cells [29,30]. Therefore, we investigated whether intracellular
ROS activation was involved in CK-induced apoptosis. SK-N-BE(2) and SH-SY5Y cells were pretreated
with or without 5 mM NAC for 3 h and then treated with CK for 24 h. ROS measurement with DCF-DA
dyes was done by fluorescence microscopy and flow cytometry (Figure 4A–C). We found that CK
treatment significantly enhanced intracellular ROS levels compared to untreated controls (Figure 4A–C).
As expected, the ROS scavenger NAC markedly blocked CK-induced ROS generation in both SH-SY5Y
and SK-N-BE(2) cells (Figure 4A–C). Through the CCK-8 assay, NAC pretreatment showed a significant
recovery of CK-induced cell death (Figure 4D), whereas NAC treatment alone did not alter ROS levels
and had no toxic effect on neuroblastoma cell viability (data not shown). In addition, we examined
the effect of CK, NAC, or CK combined with NAC on apoptosis by Hoechst 33342 and Annexin V/PI
staining (Figure 4E–H). As shown in Figure 4E,F, CK treatment significantly increased chromatin
condensation (light blue staining cells) in neuroblastoma cells, while NAC treatment significantly
inhibited chromatin condensation. In addition, CK significantly reduced Annexin V-positive cells in
the presence of NAC (Figure 4G,H). Collectively, these results suggest that ROS generation is involved
in CK-induced apoptosis of human neuroblastoma cells.
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and treated with 5 µM CK for 24 h. (A) ROS generation that occurred in CK-treated cells was measured
by fluorescence microscopy using DCFH-DA staining, and fluorescence intensity was shown as a
histogram using the Image J program. (B) Relative DCF fluorescence intensities were expressed as fold
of DCF fluorescence over the control in three groups (Control, CK, and CK + NAC). The effect of NAC
on CK-induced ROS generation was also measured by flow cytometry (C), and the percentage of cell
viability with CCK-8 assay was shown in the histogram (D). Data in B and D were shown as mean ±
SD. **: p < 0.01 versus control and ##: p < 0.01 versus CK-treated alone. (E) After cells were stained
with Hoechst 33342 dye, apoptotic bodies and chromatin-condensed nuclei (indicated by arrows) were
observed under a fluorescence microscope. Scale bar: 20 µm. (F) The bars indicate the percentage of
cells with apoptotic morphology among the total Hoechst 33342 stained cells. (G) Cells were stained
with Annexin V/PI assay by flow cytometry. (H) The percentages of apoptotic cells (Annexin V + cells)
are shown. All data (F and H) are shown as mean ± SD. **: p < 0.01 versus control and ##: p < 0.01
versus CK-treated alone.
2.5. CK Induces Early-Stage Autophagy and Autophagosome Accumulation in Human Neuroblastoma Cells
The crosstalk between autophagy and apoptotic cell death was previously reported in various
cancer cell types [10–14]. Hence, to investigate whether CK can act as an autophagy modulator, acridine
orange (AO) staining was performed in CK-treated SK-N-BE(2) cells. Because autophagy-related cell
death is characterized by the accumulation of vesicles and the formation of autophagosomes, AO
staining has been used to analyze the formation of acidic vesicle organelles (AVOs) or autolysosome
vacuoles, resulting from the fusion between autophagosomes and lysosomes, which is a key
feature of autophagy [31]. In this study, CK not only significantly enhanced the accumulation
of autophagic vacuoles (red fluorescence) in SK-N-BE(2) cells (Figure 5A), but flow cytometry
verified that the proportion of AO-positive cells was increased after CK treatment (Figure 5B).
The microtubule-associated protein light chain (LC)3 was used to monitor autophagy by detecting
the switch from LC3BI to LC3BII, and GFP-LC3 puncta was used for transfecting mammalian cells to
study autophagy [32].
For that, SK-N-BE(2) cells stably expressing GFP-LC3 were seeded, treated with increasing
concentrations of CK for 24 h, and observed using fluorescence microscopy. CK treatment markedly
increased GFP-LC3 puncta formation in cytoplasm compared with control cells (Figure 5C). Interestingly,
CK treatment exhibited a significant increase in the levels of LC3II protein in all three neuroblastoma
cells compared to the untreated control (Figure 5D,E). Beclin-1(BECN) and Atg7 proteins are required
for autophagosome formation during autophagy [33]. Treatment with CK significantly enhanced
the expression of autophagy marker proteins including BECN, Atg7, and LC3B in SK-N-BE(2) and
SH-SY5Y cells (Figure 5F–I). Taken together, these results demonstrate that CK treatment induces early
stage autophagy and autophagosome accumulation in neuroblastoma cells.
2.6. CK Inhibits Late-Phase Autophagy and the Fusion of Autophagosomes with Autolysosomes
The increase in the amount of cytoplasmic autophagosomes may result from increased synthesis
of autophagosomes through upstream processes or the inhibition of lysosomal degradation in later
stages. To confirm this possibility, we performed an autophagic flux assay by measuring the total
cellular amount of SQSTM1/p62 (sequestosome 1). SQSTM1/p62 is known as an autophagy adapter
cargo protein. It is recruited in the autophagosomal membrane and then degraded within lysosomes
along with LC3II [33]. Moreover, p62 is also considered a crucial guide of target proteins to the
autophagy system for removal from the cell [34]. Thus, downregulation of p62 protein may signify
the status of increased autophagic flux [35,36]. In the present study, western blot analysis showed
that p62 expression was remarkably increased by dose-dependent CK treatments in SK-N-BE(2) and
SH-SY5Y cells (Figure 5F–I). These results indicate that CK treatment induces the accumulation of
autophagosomes by inhibiting their degradation in neuroblastoma cells.
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Figure 5. CK treatment promotes early stage autophagy but blocks autophagic flux. (A) Acidic
vesicular organelles (AVOs) were examined by incubating SK-N-BE(2) cells treated with or without CK
in 10 µM acridine orange (AO) for 30 min, and images were captured using a fluorescence microscopy.
(B) AVO-positive SK-N-BE(2) cells were quantified by flow cytometry. Results shown are representative
of three independent experiments. (C) pEGFP-LC3B transfected stable SK-N-BE(2) cells were treated
with different concentrations of CK for 12 h, and images showing LC3-GFP puncta and accumulation
of autophagosomes were visualized under a florescence microscope. CK treatment increases GFP-LC3
punctuation. Scale bar: 50 µm. (D) The LC3B expression level was measured by western blot in
SK-N-BE(2), SK-N-SH, and SH-SY5Y cells treated with 5 µM of CK for 24 h. (E) The relative LC3B II
protein expression level was significantly increased by CK treatment in all three neuroblastoma cell
lines. (F–I) Cells were treated with various concentrations of CK for 24h in SK-N-BE(2) and SH-SY5Y
cells. Western blotting was performed with antibodies specific for BECN, Atg7, p62, LC3B, and GAPDH
in SK-N-BE(2) cells (F) and SH-SY5Y cells (H). Relative protein expression levels were shown in the
histogram (G,I), and band intensities were quantified using the Image J program. All bar graph data
(E,G,I) are shown as mean ± SD in three independent experiments. *: p < 0.05 versus control and
**: p < 0.01 versus control.
Chloroquine (CQ) is a specific late-phase autophagy inhibitor, which inhibits autophagic
flux by decreasing autolysosome degradation and, is widely u d to inhibit the maturatio
of autophagosomes into degradative autolysosomes [37,38]. Tandem fluorescence-tagged LC3B
(monom ric red fluoresce ce protein mRFP-GFP-LC3B protein; tfLC3) as used to confirm wheth r CK
treatment can inhibit late-stage autophagy a d then cause p62 accumulati n. To monitor autophagic
flux fr m autophagosome to autolysosome, GFP and RFP signals showing different pH sensitivity are
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widely used because GFP signals are quantitatively quenched in acidic compartments, whereas RFP
fluorescence is maintained. Therefore, this probe capitalizes on the pH difference between autolysosome
(acidic) and autophagosome (neutral), which denotes autophagic flux from autophagosomes (GFP +
RFP +; yellow dots) to autolysosomes (GFP - RFP +; red dots).
As shown in Figure 6A,B, the number of red puncta was increased in Earle’s balanced salt solution
(EBSS)-treated cells (positive control), indicating that autophagy flux was increased. Similar to cells
with CQ (10 µM) alone, increased formation of yellow puncta was observed in 5 µM CK-treated
SK-N-BE(2) cells without increasing the number of red puncta (Figure 6A,B). Moreover, a CK and CQ
combination treatment on SK-N-BE(2) cells further increased the levels of LC3-II and p62 expression in
SK-N-BE(2) cells pretreated with CK (5 µM) (Figure 6C,D). Taken together, these results demonstrate
that CK blocks fusions between autophagosomes and autolysosomes similar to CQ, indicating that CK
can act as a potent autophagy inhibitor.Int. J. Mol. Sci. 2019, 20, x 11 of 24 
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in EBSS for 24 h. The treated cells were fixed and imaged with fluorescence microscopy. Scale bar:
50 µm. (B) Quantitative analysis of double positive (GFP + /RFP +) and single positive (RFP +) puncta
per cell in control, Earle’s balanced salt solution (EBSS)-, CQ-, and CK-treated cells. Data are the mean
values of three independent experiments with each count. Values are expressed as the mean ± SD.
**: p < 0.01 versus control. (C) CK increased p62 and LC3B-II expression. SK-N-BE(2) cells were treated
with CK for 24 h with or without CQ (10 µM). (D) The protein level of LC3B and p62 was analyzed by
western blot. Results were normalized to GAPDH. Data are presented as mean ± standard deviation
(SD). ***: p < 0.001 versus CK-treated cells. CK, Ginsenoside compound K; CQ, chloroquine.
2.7. CK and CQ Combination Therapy Enhances CK-Induced Apoptosis in Human Neuroblastoma Cells
Inhibition of autophagy leads to cancer cell death because autophagy has been proposed as a
cancer cell survival mechanism in cancer treatment [16]. To inve tigate the functi n l relationship
between autophagy and apoptosis after CK treatment, we pretreated human neuroblastoma cells
with either CQ (10 µM) or rapamycin (RAPA, 100 nM) before CK treatment (5 µM). As an autophagy
inducer, RAPA inhibits mTOR, thus, enhancing autophagy [39]. As shown in Figure 7A, co-treatment
of CQ and CK significantly decreased cell viability compared to CK alone in SK-N-BE(2) and SH-SY5Y
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neuroblastoma cells. Furthermore, western blot results showed that CQ and CK co-treatment increased
cleaved caspase-3 and cleaved PARP levels compared with CK alone in SK-N-BE(2) cells (Figure 7B).
Consistent with the results of our western blot analysis, immunostaining analysis demonstrated that
the CQ and CK combination treatment increased the expression of cleaved caspase-3 higher than CK
alone performed in SK-N-BE(2) cells (Figure 7C).
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Figure 7. Inhibition of autophagy promotes CK-induced apoptosis via mitochondrial membrane ROS
and mitochondrial membrane potential loss in human neuroblastoma cells. (A–D) Cells were pretreated
with 10 µM CQ for 3 h prior to the treatment with CK 5 µM for 24 h. (A) SK-N-BE(2) and SH-SY5Y
cell viability was determined by CCK-8 assay after 24 h incubation. (B) The protein levels of PARP,
cleaved aspase-3, and PCNA in SK-N-BE(2) cells were analyzed by western blot. (C) Immunostaining
was performed with cleaved caspase-3 and PCNA antibodies in SK-N-BE(2) cells. (D) Apoptotic cell
death was evaluated by Annexin V/PI analysis with flow cytometry in SK-N-BE(2) a d SH-SY5Y cells.
Data (A) and (D) are presented as mean ± SD. **: p < 0.01 versus control cells, and ##: p < 0.01 versus
CK-treated cells. (E,F) SK-N-BE(2) cells were treated with 5 µM CK with or without CQ (10 µM) or
rapamycin (RAPA) (100 nM) for 24 h. (E) The MitoSOX™ Red fluorescence intensity was detected
by fluorescence microscopy. (F) The corresponding histograms were quantified by Image J. All data
are represented as mean ± SD (N = 3) for each group. *: p < 0.05, **: p < 0.01. (G) To determine
mitochondrial membrane depolarization, SK-N-BE(2) cells stained with Rhodamine123 dyes were
analyzed by flow cytometry. (H) Data are presented as mean ± SD (n = 3) for each group. **: p < 0.01.
CK, Ginsenoside compound K; CQ, chloroquine.
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To investigate anti-proliferation effects of the combination treatment with CQ and CK, we examined
the expression of proliferating cell nuclear antigen (PCNA), which is a marker of cell proliferation.
As a result, we found that the expression levels of PCNA proteins were downregulated to a greater
extent with combinatorial treatment with CK and CQ than in CK alone (Figure 7B,C). Next, we
examined the rate of cell death by the Annexin/PI method to investigate the effect of CQ and RAPA
(100 nM) on CK-induced apoptosis in neuroblastoma cells (Figure 7D). Compared with the control
group, CK treatment induced an increase in apoptosis rate, and the co-treatments with CQ further
increased apoptosis rate compared to CK alone. However, RAPA treatment did not affect apoptosis
rate (Figure 7D). Consequently, the CQ and CK combination treatment not only increased apoptotic
cell death but also decreased the survival rate in neuroblastoma cells. Overall, these data strongly
suggest that combined treatment with CQ and CK enhances more significant synergistic effects on
apoptotic cell death in neuroblastoma than CK treatment alone.
Moreover, to investigate the mechanisms of CK-induced toxicity, mitochondrial ROS levels
and mitochondria membrane potential (MMP) (∆ψm) were also measured in SK-N-BE(2) cells. The
MitoSOXTM Red reagent was used for detecting superoxide in the mitochondria of CK-induced
living cells. MitoSOX fluorescence intensity was clearly increased in CK-treated SK-N-BE(2) cells
(Figure 7E,F). The production of mitochondrial ROS, in which CQ and CK coexist, was significantly
increased compared with the CK alone group. However, this effect was not found in the group treated
with RAPA and CK together (Figure 7E,F). Next, we used Rhodamine 123, a sensitive fluorescent
dye, as an indicator of mitochondrial dysfunction to measure MMP (∆ψm) levels (Figure 7G,H). The
measured MMP depolarization was significantly accelerated in the combination treatment with CQ
in SK-N-BE(2) cells compared to CK alone, but those effects were not found in cells treated with
RAPA and CK together (Figure 7G,H). Taken together, these results demonstrate that the CQ and CK
combination treatment promotes CK-induced apoptosis through the production of mitochondrial ROS
and mitochondrial signaling pathways in neuroblastoma cells.
2.8. CQ and CK Combination Treatment Improves the Anti-tumor Effect of CK in Neuroblastoma
Xenograft Models
To investigate the effect of the CQ and CK combination treatment on neuroblastoma cell line
in vivo, a subcutaneous xenograft tumor model was established by inoculating SK-N-BE (2) cells into
athymic nude mice. As shown in Figure 8A,B, CK treatment (30 mg/kg) significantly inhibited tumor
growth in comparison with the vehicle-treated groups, and combination treatment with CK and CQ
had a more remarkable anti-tumor effect than CK treatment alone, whereas treatment with only CQ
did not show any inhibition of tumor growth. Moreover, the combination treatment also significantly
reduced the tumor weight (Figure 8C), but there was no significant body weight change between each
animal group (data not shown). The reduction of tumor size in mice treated with CK and combination
treatment (CK and CQ) was associated with the increased expression of cleaved caspase 3- as well as
TUNEL-positive cells (Figure 8D). Collectively, these data suggest that inhibition of autophagy by CQ
may further enhance the anticancer effect of CK in vivo.
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Figure 8. Inhibition of autophagy by CQ improves the CK-induced anti-tumor effect in neuroblastoma
xenograft models. (A–C) Athymic nude mice bearing isogenic SK-N-BE(2) xenograft tumors were
treated with vehicle (dimethyl sulfoxid , DMSO), CQ (50 mg/kg), CK (30 mg/kg), and CK in combination
with Q via intraperit eal injection three times a week. Mice were sacr ficed, and tumor sampl s we e
collecte 61 days after c ll inj ction. (A) The picture of different tumor groups. (B) Tumor growth curves
represented the average values of 5 mice in each group. (C) Tumor weight s expressed in a scatter
plot. Data (B) and (C) are pre en d as mean ± SD. **: p < 0.01, ***: p < 0.001 versus vehicle (DMSO
treatment). (D) In eac mouse tumor s mple group, apoptosis was xamined by immunohistochemical
staining with cleaved caspase 3 antibody and TUNEL assay. Scale bar, 20 µm.
3. Discussion
In this study, we demonstrate that CK induced apoptosis and ROS generation and inhibited
autophagy flux in neuroblastoma cells in vivo and in vitro. Interestingly, chloroquine, an autophagy
flux inhibitor, potentiates CK-induced apoptosis. Apoptosis is a systemically well-organized suicide
program that removes defective, damaged, or unwanted cells. Autophagy is also an intracellular
system that removes cytosolic protein aggregates, damaged organelles, and infectious organisms and
contributes to cell survival mechanisms [15,40]. Apoptosis and autophagy are two distinct processes
required to maintain homeostasis of cells. In addition, the crosstalk between autophagy and apoptotic
cell death was reported in many cancer cell types [10–14]. Hence, we investigated the molecular
mechanisms of CK on neuroblastoma cell growth inhibition, cell death, and autophagy to understand
the complexity of the relationship between cancer cell apoptosis and autophagy.
Firstly, we found that the growth inhibition by CK in three human neuroblastoma cell lines,
such as SK-N-BE(2), SH-SY5Y, and SK-N-SH cells, were dose-dependent (Figure 1B–D), and we also
demonstrated that CK induced the accumulation of sub-G1 population (apoptotic cells) and apoptosis
in a caspase-dependent manner. We also found that CK significantly inhibited autophagic flux by
blocking of autophagosome and lysosome fusion, the step of late-stage autophagy. Similar to our
study, CK exerts anticancer effect by triggering apoptosis and autophagy via ROS generation on colon
cancer cells [28]. In addition, there is ample evidence that demonstrated that CK has an antitumor
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effect on various cancers by triggering apoptosis, inhibiting proliferation, or inducing autophagy
through multiple pathways [27,41–45]. However, previous studies have limited results such as acting
as an autophagy inducer in colon cancer or non-small lung cancer [28,46] or inhibiting cell death by
autophagy after brain injury [47]. Thus, the anticancer effect of CK will be controversial whether it
contributes to apoptosis or not. In this context, the present study is first to show that CK inhibits
autophagy flux in neuroblastoma. It also suggests that that natural product CK can be used for not
only inducing apoptosis but also inhibiting autophagic flux in neuroblastoma.
Another cell death type, autophagic cell death (ACD) is an evolutionarily conserved catabolic
process that requires the formation of autophagosomes and various autophagy-related proteins,
including Atgs, BECN, and LC3B [33,48]. Autophagic flux is defined as a measure of autophagic
degradation activity, and LC3-II and p62 are widely used as indicators for the measurement of
autophagic flux [49–51]. In this study, CK-induced early-stage autophagy in neuroblastoma cells was
evidenced by an increased number of autophagosomes and increased expression of the autophagy
markers LC3-II, Atg7, and BECN proteins (Figure 5). Additionally, autophagic flux analysis showed
that CK treatment induces an increase in p62 expression. Furthermore, CK inhibited autophagic flux
by blocking the autophagosome–autolysosome fusion process in neuroblastoma cells, similar to CQ,
a late-stage autophagy inhibitor (Figure 6A). According to our results, p62 expression was upregulated
by CK treatment in a dose-dependent manner in neuroblastoma cells (Figure 5E,F). Consistent with
our data, recent studies demonstrate that upregulation of p62 expression is associated with ACD in
breast cancer [52], hepatocellular carcinoma cells [53], and esophageal cancer [54].
The role of autophagy in the treatment of cancer remains still unclear. In many solid tumors,
including NB, after chemotherapy, autophagy acts as a survival mechanism of cancer cells, by which
it can reduce the effectiveness of chemotherapy [2,55]. Extensive autophagy can lead to cell death,
and although autophagy is thought to have a dual role in tumorigenesis, its function is yet to be fully
understood [56–59]. Thus, identification of a clear interaction between autophagy and apoptosis could
be an effective approach for cancer treatment. Among the inhibitors of autophagy, chloroquine (CQ),
a specific late-phase autophagy inhibitor, inhibits lysosome fusion to the autophagosome and impairs
autophagosome maturation into degradative autolysosomes [37,38]. Currently, CQ has been used in
cancer clinical trials. Thus, the combination of chloroquine and CK might be a promising strategy
in the treatment of neuroblastoma. In the present study, we identified the anti-NB cancer activity
of CK through in vitro and in vivo experiments (Figures 1–4, 7 and 8). Additionally, CK inhibited
autophagic flux through blockade of autophagosome and autolysosome fusion in neuroblastoma. This
suppression of autophagy with the autophagy inhibitor CQ could significantly enhance CK-induced
apoptosis in neuroblastoma cells. More detailed studies found that CK not only stimulated the
generation of intracellular ROS, which subsequently triggered mitochondria dysregulation, but also
inhibited autophagic flux. However, the relationship between increased ROS level and autophagic flux
inhibition by CK remains to be revealed through further studies. This observation has demonstrated
the cytoprotective role of autophagy in CK-treated neuroblastoma cells, suggesting that abolition of
autophagy can improve the anti-NB cancer effect of CK in vitro. We also noted that the SK-N-BE (2)
cell xenograft model confirms the protective effect of autophagy on CK therapy in vivo. As a result,
the combination therapy of CK and CQ enhanced the therapeutic effect of CK, which proved that
autophagy blocking could further increase the therapeutic effect of NB cells.
Under normal circumstances, ROS formed by the mitochondrial respiration is removed by
antioxidant enzymes. However, excessive ROS build-up due to the inhibition of antioxidant activity
is toxic to cells [60]. This abnormal ROS production leads to MMP loss, causing leakage of various
apoptotic molecules from the mitochondria into the cytoplasm, leading to apoptosis. Thus, ROS is
an important mediator of intracellular signaling pathways, including the mitochondrial-mediated
apoptosis pathway [60,61]. Recently, a change in ROS level has also been reported to be associated
with autophagic death [62–64]. Our present results also found that CK-treated neuroblastoma cells
have an increased level of intracellular ROS compared to control cells (Figure 3A–C); however, the
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ROS scavenger NAC significantly reduced ROS production and rescued cell death induced by CK
treatment (Figure 3A–D). Interestingly, the CQ and CK combination treatment induced a significant
increase in mitochondrial ROS production and loss of MMP compared with CK only treatment, but not
RAPA treatment (Figure 6E–H). Additionally, inhibition of autophagy can exacerbate mitochondrial
damage and promote mitochondrial-dependent apoptosis in neuroblastoma cells (Figure 6A–D). These
results indicate that autophagy can play a protective role against CK-induced apoptosis by eliminating
damaged mitochondria. However, further studies on the underlying molecular mechanisms of
ROS-mediated apoptosis and autophagy with CK treatment are needed.
One of the advantages in our study is that low concentrations of CK were used against
neuroblastoma cells. There are many studies that have reported the inhibitory effect of CK on
the growth of various cancer cells, and IC50 for HL-60, K562, PC-14, MKN-45, Du145, HCT116, and
U373MG were at 11.7, 8.5, 25.9, 56.6, 58.6, 30–50, and 15 µM, respectively [41–45]. In our study, IC50
values with CK treatment were 5 µM in SK-N-BE(2) cells, 7 µM in SH-SY5Y cells, and 15 µM in SK-N-SH
cells, respectively (Figure 1B–D). It showed a definitely low concentration of CK in neuroblastoma
compared to other cell lines, and neuroblastoma cells are much more sensitive to CK than other
cancer cells. More importantly, cytotoxicity was not found in normal cells including HUVEC, BJ, and
CCD-1079SK cells (Figure 1E–G). This suggests that CK may be a good candidate for NB therapy.
Our data provide a preliminary insight into the potential use of CK as an anticancer drug for NB
cancer treatment. In addition, further studies are needed to know the mechanism or regulation of
cancer-specific effects of CK, and it will be interesting.
Overall, we demonstrate that ginsenoside compound K induced ROS generation-mediated
apoptosis and inhibited autophagy flux in neuroblastoma cells (Figure 9). Moreover, chloroquine, an
autophagy flux inhibitor, potentiates CK-induced apoptosis in vitro and in vivo. To our knowledge,
we first report the anticancer effect of CK combination with chloroquine against neuroblastoma cells.
The findings suggest that a combination strategy of the ginsenoside CK with chloroquine (autophagy
inhibitor) could be a novel therapeutic potential for the treatment of neuroblastoma.Int. J. Mol. Sci. 2019, 20, x 16 of 24 
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Figure 9. Schematic representation of the proposed mechanisms of CK-induced apoptosis in
neuroblastoma cells. CK induced caspase-dependent apoptosis and ROS generation and inhibited
autophagy flux. Importantly, ROS scavenger NAC markedly blocked CK-induced ROS generation
and apoptosis. Moreover, chloroquine, an autophagy flux inhibitor, augmented the CK-induced
apoptosis, mitochondrial ROS generation. Altogether, a combination treatment of CK with chloroquine,
a pharmacological inhibitor of autophagy, may be a novel therapeutic potential for the treatment
of neuroblastoma.
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4. Materials and Methods
4.1. Chemicals and Reagents
CK (purity > 97%) was prepared by a transformation of PPD-type ginsenosides extracted from
Korean ginseng using acid-heat treatment. N-acetyl-L-cysteine (NAC), dimethyl sulfoxide (DMSO),
2′,7′dichlorodihydrofluorescein diacetate (DCFH-DA), Carbonyl cyanide m-chlorophenyl hydrazone
(CCCP), rapamycin (RAPA), acridine orange (AO), chloroquine (CQ), and an in situ cell death detection
kit (TMR red; TUNEL) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).
Dulbecco’s modified eagle medium (DMEM), fetal bovine serum (FBS), 0.05% Trypsin-EDTA and
penicillin-streptomycin were purchased from Gibco BRL (Grand Island, NY, USA). The following
antibodies were used: LC3-I/II was purchased from Sigma; GAPDH, Bcl-2, cleaved caspase-3, caspase-8,
PCNA, ATG7, Beclin 1, and p62 (Cell Signaling, Danvers, MA, USA), PARP and Bcl-xL (Santa Cruz
Biotechnology, Dallas, TX, USA), Alexa 488/594 conjugated secondary antibodies (Abcam, Cambridge,
UK), Annexin V-FITC apoptosis detection kit, propidium iodide (PI), Hoechst 33342 staining kit, and
Z-VAD-FMK were purchased from BD Biosciences (SanJose, CA, USA).
4.2. Cells and Culture Conditions
Human neuroblastoma (SH-SY5Y and SK-N-BE(2)), human foreskin fibroblasts (CCD-1079SK,
and BJ), and human umbilical vein endothelial cell (HUVEC) lines were obtained from the American
Type Culture Collection (Manassas, VA, USA). SK-N-SH cells were obtained from the Korean Cell Line
Bank (Seoul, Korea). Cells were cultured in DMEM supplement with 10% (v/v) heat-inactivated FBS
and 1% (v/v) penicillin-streptomycin in a humidified incubator with 5% CO2 atmosphere and 37 ◦C.
CK was prepared in 100% dimethyl sulfoxide, stored in small aliquots at −80 ◦C and diluted in the cell
culture medium as needed.
4.3. Cell Viability Assay
Cell viability was assessed using the cell count kit-8 (Dojindo Molecular Technologies, Tokyo,
Japan) assay. Cells were seeded in the 96-well plates (1× 104/well) and exposed to various concentrations
of CK (2, 5, 10, 15, 20 µM) for 24 h. Pretreated with NAC (5 mM), CQ (10 µM), RAPA (100 nM), and
Z-VAD-FMK (20 µM) for 3 h and then exposed to either with or without 5 µM CK for 24 h. Cells
without addition of CK were taken as control. The medium was then removed, and 10 µL of the CCK-8
solution was added to each well of the plate. After 3 h incubation, the absorbance was measured at
450 nm using a microplate reader Synergy TM (BioTek Instruments, Inc., Winooski, Vermont, USA).
The cell viability was expressed as the percentage of the control, which was set to 100. All experiments
were performed in triplicate and repeated at least three times. The 50% inhibitory concentration (IC50)
was obtained from the dose-response curve of percent viability (Y) versus tested concentrations (X).
IC50 was calculated using linear regression analysis in Microsoft Excel.
4.4. Colony Formation Assay
For colony formation assay, SK-N-BE(2) and SH-SY5Y cells were placed into a 6-well plate at
a density of 1 × 103 cells/well and incubated with different concentrations of compound K at 37 ◦C
for 24 h. The medium was then replaced freshly every day, and cells were grown for 14 days. After
staining with 0.5% crystal violet for 30 min, the colonies were visualized and quantified.
4.5. Cell Cycle Analysis
SK-N-BE(2) cells were seeded onto 6-well plates at a density of 5 × 105 cells/well and treated with
various concentrations of CK for 24 h. Floating and adherent cells were collected with trypsin-EDTA
(Sigma-Aldrich) and fixed in 70% ethanol overnight at −20 ◦C. The cells were washed with cold
phosphate buffered saline (PBS) and stained with PI (100 µg/mL) in the dark at 37 ◦C for 30 min.
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Then, 10,000 fluorescent events were measured and analyzed with an Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA, USA).
4.6. Hoechst 33342 Staining
For the Hoechst 33342 staining, SK-N-BE(2) and SH-SY5Y cells were pretreated with 5 mM NAC
for 3 h and treated with 5 µM CK for 24 h. The cells were washed with cold PBS and then fixed with
cold methanol and stained with Hoechst 33342 (1 µg/mL) for 10 min. The morphology was examined
by fluorescence microscopy (CELENA S, Logos Biosystems, Anyang, Korea).
4.7. Apoptosis Assay with Annexin V and PI Staining
Apoptotic cell death was determined using apoptosis detection kit (Annexin V-PI: BD Biosciences,
San Jose, CA, USA). Briefly, 5 × 105 cells were treated with CK (0, 5, 10, and 20 µM) for 24 h. Cells
were harvested and washed once with PBS, and stained with 5 µL of Annexin V-FITC and 5 µL of
propidium iodide (PI) for 30 min at 37 ◦C. The stained cells were analyzed by Accuri C6 flow cytometry.
Apoptotic cells (Annexin V-FITC + /PI− and Annexin V-FITC + /PI +) were counted and presented as a
percentage of the total cell count.
4.8. Mitochondrial Membrane Potential (∆ψm) Assay
Cells (2 × 105) were seeded on 6-well plates and treated with either with or without CK for 24 h.
Mitochondrial membrane potential changes were monitored by rhodamine 123 using flow cytometry.
In brief, cells were incubated with rhodamine 123 (0.1 µg/mL) for 30 min at 37 ◦C and collected. The
fluorescent intensity was measured using flow cytometry. The positive control was treated with CCCP.
4.9. Hoechst 33342 and PI Staining
The levels of nuclear condensation and fragmentation were observed by Hoechst 33342 (1 µg/mL)
and PI (1 mg/mL). Cells were grown on cover slips and treated with CK at various concentrations (0, 5,
10, and 20 µM) after 24 h. Cells were washed twice with cold phosphate buffered saline (PBS), and
fixed in cold methanol for 10 min at room temperature. The fixed cells were washed twice with PBS.
The stain solution was dropped on a glass slide and incubated for 20 min at 37 ◦C, and coverslips were
placed on a glass slide prior to the observation by a fluorescence microscopy. Four visual fields were
randomly selected from each sample and data were collected from three independent experiments. The
cell death rate (%) was expressed as the ratio of PI positive stained cells in total Hoechst stained cell.
4.10. RNA Isolation and Reverse Transcription (RT)-PCR
Total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s protocol, and 5 µg of RNA was used for complementary DNA (cDNA) synthesis using
synthesized using Go Script reverse transcription system (Promega, Madison, WI, USA). PCR was
carried out with specific primers. The PCR products were electrophoresed on 1.2% agarose gel and
visualized on a UV transilluminator using Red Safe (iNtRON Biotechnology, Seongnam, Korea).
The relative expression level of a target gene was quantified by normalization with the internal
control GAPDH gene. Primers used in the experiment were as follows: (1) human Bax (forward)
5′-TCTGACGGCAACTTCAACTG-3′ and (reverse) 5′-TCCCGCCACAAAGATGGTCACG-3′;
(2) human Bcl-2 (forward) 5′-GAGGATTGTGGCCTTCTTTG-3′ and (reverse) 5′-ACAGTTCCACAA
AGGCATCC-3′; (3) human Caspase-3 (forward) 5′-TTTGT TTGTGTGCTTCTGAGCC-3′ and (reverse)
5′-ATTCTGTTGCCACCTTTCGG-3′; (4) human Caspase-9 (forward) 5′-AACAGGCAAGCAGCAAA
GTT-3′ and (reverse) 5′-TCCATCTGTGCCGTAGACAG-3′; (5) human Puma (forward) 5′-AGTGTCCT
GCGGCCTCTG-3′ and (reverse) 5′-GGAGTCCCATGATGAGATTGT-3′; (6) human Noxa (forward)
5′-CGGAGATGCCTGGGAAGAA-3′ and (reverse) 5′-AGGTTCCTGAGCAGAAGAGT-3′; (7) human
GAPDH (forward) 5′-GAGTCAACGGATTTGGTCGT-3′ and (reverse) 5′-GACAAGCTTCCCGTT
CTCAG-3′.
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4.11. Western Blot Analysis
After treated with various stimuli, cells were lysed for 30 min in radioimmunoprecipitation
assay (RIPA) buffer supplemented with protease and phosphatase inhibitor cocktail (Thermo Fisher
scientific, Waltham, MA, USA). The samples were heated to 100 ◦C for 5 min and placed on ice.
Whole cell extracts (30 µg protein) were loaded onto a 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel and transferred onto a polyvinylidene fluoride (PVDF) membrane
(Millipore, Burlington, MA, USA). The membrane was blocked with 5% milk or 5% BSA for 1 h at
room temperature (RT), and incubated overnight with primary antibodies, followed by horseradish
peroxidase (HRP)-conjugated secondary antibodies for 1 h at RT. The blot bands were detected with an
enhanced chemiluminescence (GE Healthcare, Piscataway, NJ, USA).
4.12. Measurement of Intracellular ROS Generation
The generation of ROS was evaluated by fluorescence microscopy and flow cytometry. ROS
production was measured using the dye DCFH-DA (Sigma, MO, USA), as previously described [31,65].
For flow cytometry, cells treated with or without CK for 24 h were rinsed with cold PBS and incubated
in 10 µM DCFH-DA for 30 min at 37 ◦C in the dark. DCF fluorescence was measured using Accuri
C6 FACS (BD Biosciences, San Jose, CA, USA), and data was analyzed using Accuri C6 program (BD
Biosciences, San Jose, CA, USA). For fluorescence microscopy, cells were seeded on coverslips and
treated with or without CK for 24 h. Cells were incubated in 10 µM DCFH-DA for 30 min at 37 ◦C
in the dark, rinsed with cold PBS, and imaged under a fluorescence microscopy. On average, three
microscope fields were quantified in three separate cultures per treatment condition. Image J was used
to quantify fluorescence intensity. The results were expressed as percentage change from the controls.
4.13. Immunofluorescence Staining
Cells were cultured on coverslips and pretreated with 10 µM chloroquine for 3 h prior to treating
with 5 µM CK for another 24 h. Cells were then washed twice in PBS, fixed with cold methanol, and
permeabilized with 0.2% Triton X-100 in PBS for 20 min. After blocking with 10 % normal goat serum for
1 h, and incubated overnight at 4 ◦C with primary antibodies (cleaved caspase-3 and PCNA), washed
three times in PBS, and incubated in Alexa 488-conjugated anti-rabbit IgG or Alexa-594-conjugated
anti-mouse IgG for 1 h. Nuclei were counterstained using Hoechst 33342 (BD Biosciences, San Jose,
CA, USA), and the stained cells were observed under a fluorescence microscopy CELENA S. Images
were analyzed using ImageJ software version 1.52a (NIH, Bethesda, MD, USA).
4.14. Detection of Autophagic Vacuoles by Acridine Orange Staining (AO)
A fluorescent compound, acridine orange (Sigma, St. Louis, MO, USA) is commonly used to
measure DNA and RNA levels in cells and can also be used to detect the level of acidic granule
compartments within cells undergoing autophagy [66]. Formation of acidic vesicular organelles (AVOs)
was quantitated by acridine orange staining [66,67]. SK-N-BE(2) cells (5 × 105/well) were cultured in
24-well culture plates and treated without or with CK (5 µM) for 24 h, then cells were stained with
5 µg/mL acridine orange (Sigma) for 15 min at 37 ◦C. After washed with PBS, cells were examined
under a fluorescence microscope and analyzed by flow cytometry using the Accuri C6 program.
4.15. Plasmids Construction
For the generation of enhanced green fluorescent protein-LC3 (EGFP-LC3) transfection vector,
the full length of human microtubule-associated protein 1 light chain 3 (LC3; GenBank accession no.
NM_022818.5) was amplified by RT-PCR using forward (5′-GTTCTCGAGCTATGCCGTCGGAGAA
GA-3′) and reverse (5′-AAGGATCCTTACACTGACAATTTCATCC-3′) primers, and the SK-N-BE(2)
cDNA was used as template. The PCR fragment of LC3 protein was digested using with XhoI and
BamHI (Enzynomics, Daejeon, Korea) and was cloned into pEGFP-C1 plasmid (Clontech, Palo Alto,
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CA, USA). All constructs were verified by sequencing. The mRFP-GFP-LC3 expression plasmid was a
generous gift from Jaerak Chang (Ajou University, Suwon, Korea).
4.16. Cell Transfection and Stable Cell Screening
Transient transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocols. SK-N-BE(2) cells were cultured in DMEM (Gibco)
containing 10% fetal bovine serum (FBS) and antibiotics in 5% CO2 at 37 ◦C. When the confluence
reached 70% in 6-well culture plates and then transfected with 5 µg plasmid per well (plasmid (µg):
Lipofectamine 2000 (µL) = 1:3). Forty-eight hours after transfection, cells were digested with 0.25%
trypsin and the cultures were transferred to the plates for further culture with complete DMEM
containing 1000 mg/L G418 for 14 days. When the amount of resistant cell clones was observed, they
were digested with 0.25% trypsin and then transferred to a new culture flask using an aseptic pipette
for further culture. Selected cells were used for additional autophagy analysis.
4.17. Detection of GFP-LC3 or mRFP-GFP-LC3B Assay
After the pEGFP-LC3 or mRFP-GFP-LC3B stable SK-N-BE(2) cells were treated with CK or/and
CQ for 24 h, the cells were fixed, and mounted. Images from slides were observed under a fluorescence
microscope CELENA S.
4.18. Measurement of Mitochondrial ROS Generation
The formation of mitochondrial ROS was measured using MitoSOXTM Red (Life technologies,
Eugene, OR, USA) assay. MitoSOXTM Red reagent is oxidized by superoxide once inside the
mitochondria, and is converted to a fluorogenic oxidation product upon binding to nucleic acids [68].
For microscopy, cells were treated with 5 µM CK for 24 h in the presence or absence of CQ and RAPA.
After staining with MitoSOXTM Red, images were collected using a fluorescence microscopy. Mean
fluorescence intensity of images was analyzed using the Image J.
4.19. Tumor Xenograft Studies
Animal studies were performed as described previously [69]. The mice were maintained in
a specific pathogen free environment. SK-N-BE(2) cells (3 × 107) in 100 µL (PBS: Matrigel = 1:1)
were injected subcutaneously into the right flank of each mouse. A week after, tumor injected mice
were randomly divided into vehicle, CK, CQ, and CK + CQ groups (n = 5 per group). The vehicle
group was given DMSO, and the treatment groups were injected with CK (30 mg/kg), CQ (50 mg/kg)
(Sigma-Aldrich) or both drugs, respectively. All drug injection was administered intraperitoneal
three times per week. Body weight and tumor volume were also measured three times a week, and
the tumor volume was calculated using the following formula: tumor size (mm3) = pi/6 × (length ×
width × height). Tumor inoculated mice were sacrificed after 60 days. All experimental procedures
were approved by the Institutional Animal Care and Use Committee of Chonbuk National University
(permit number: CBNU-2018-013).
4.20. Histology and TdT-Mediated dUTP Nick end Labelling (TUNEL)
All immunohistochemistry experiments were performed as described previously [69].
Paraffin-embedded samples were sliced into 4 µm sections. After antigen retrieval, tissue samples
were blocked using blocking buffer (5% goat serum) for 30 min. After washed three times with PBS,
samples were incubated in primary antibody (cleaved caspase 3, 1:250) at 4 ◦C overnight. After washed
three times with PBS, samples were incubated for 1 h at RT with an Alexa-488 conjugated antibody.
TdT-mediated dUTP nick end labelling (TUNEL) was performed with an In Situ Cell Death Detection
(TMR red) Kit (Sigma; St. Louis, MO, USA) according to the manufactured instructions.
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4.21. Statistical Analysis
All experiments were performed in triplicate and data were expressed as mean ± standard
deviation (SD). Statistical analysis was performed using SPSS (version 12.0, SPSS Inc., Chicago, IL,
USA). Significant differences between treatment effects were determined by one-way analysis of
variance or two-tailed Student’s t-test analysis, and p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) were
considered statistically significant.
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Abbreviations
CK Compound K
ROS Reactive Oxygen Species
PPD ProtoPanaxaDiol
AO Acridine Orange
PCNA Proliferating Cell Nuclear Antigen
CCK-8 Cell Count Kit-8
CQ Chloroquine
RAPA Rapamycin
AVOs Acidic Vesicle Organelles
MMP Mitochondria Membrane Potential
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